Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Autologous Human Schwann Cells in Peripheral Nerve Repair

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03999424
Recruitment Status : Recruiting
First Posted : June 26, 2019
Last Update Posted : September 26, 2019
Sponsor:
Collaborator:
The Miami Project to Cure Paralysis
Information provided by (Responsible Party):
W. Dalton Dietrich, University of Miami

Brief Summary:
The purpose of this study is to assess the safety of autologous human Schwann cell (ahSC) augmentation of nerve autograft repair in participants with severe peripheral nerve injury (PNI). For humans with acute severe PNI, the hypothesis is that augmentation of nerve autograft repair with ahSCs can potentially enhance axonal regeneration and myelin repair and thus improve functional recovery.

Condition or disease Intervention/treatment Phase
Peripheral Nerve Injuries Biological: autologous human Schwann cells Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: The Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury
Actual Study Start Date : September 24, 2019
Estimated Primary Completion Date : September 1, 2029
Estimated Study Completion Date : September 1, 2029

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Autologous human Schwann cells
All participants will receive autologous human Schwann cells harvested from their own sural nerve.
Biological: autologous human Schwann cells
Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix




Primary Outcome Measures :
  1. Number of participants with reported adverse events (AEs) [ Time Frame: 12 months post-transplantation ]
    The number of participants with reported AEs will be evaluated to assess safety. Using CTCAE v4.0 grading scale, all AEs that are Grade 3 or higher with treating physician's attribution of probable or definite relation to intervention will be included.

  2. Number of participants with reported cell product culture test failure [ Time Frame: 12 months post-transplantation ]
    Using sterility testing, the number of participants with reported cell product culture test failure will be evaluated.

  3. Change in muscle strength scale grade of affected limb muscles [ Time Frame: from baseline to 12 months post-transplantation ]
    The Medical Research Council (MRC) scale for muscle strength grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle.

  4. Sensory recovery scale grade of affected dermatomes [ Time Frame: from baseline to 12 months post-transplantation ]
    Assessment of pin-prick and two point discrimination in areas previously anesthetic in the distal distribution of the nerve injury.

  5. Change in pain scores [ Time Frame: from baseline to 12 months post-transplantation ]
    The Douleur Neuropathique 4 (DN4) questionnaire estimates the probability of neuropathic pain, based on 10 items. Seven items related to pain quality are based on an interview and 3 items are based on clinical examination.

  6. Change in pain characteristics (location, intensity, and description) [ Time Frame: from baseline to 12 months post-transplantation ]
    Assessed by a pain diagram which identifies areas of pain with descriptors. An intensity scale from 0 (no pain) to 10 (most intense pain imaginable) is used to rate the overall intensity of pain at the time of assessment.

  7. Number of participants with reported tumorigenesis or unexpected changes in nerve structure [ Time Frame: 2 years post-transplantation ]
    Tumorigenesis and/or unexpected changes in the nerve structure will be determined by evaluation of magnetic resonance imaging (MRI).


Secondary Outcome Measures :
  1. Change in muscle strength scale grade of affected limb muscles [ Time Frame: from baseline to 5 years ]
    The Medical Research Council (MRC) scale for muscle strength grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle.

  2. Sensory recovery scale grade of affected dermatomes [ Time Frame: from baseline to 5 years ]
    Assessment of pin-prick and two point discrimination in areas previously anesthetic in the distal distribution of the nerve injury.

  3. Change in pain scores [ Time Frame: from baseline to 5 years post-transplantation ]
    The Douleur Neuropathique 4 (DN4) questionnaire estimates the probability of neuropathic pain, based on 10 items. Seven items related to pain quality are based on an interview and 3 items are based on clinical examination.

  4. Change in pain characteristics (location, intensity, and description) [ Time Frame: from baseline to 5 months post-transplantation ]
    Assessed by a pain diagram which identifies areas of pain with descriptors. An intensity scale from 0 (no pain) to 10 (most intense pain imaginable) is used to rate the overall intensity of pain at the time of assessment.

  5. Nerve-graft continuity [ Time Frame: 2 weeks post-transplantation ]
    Ultrasound will be used to assess nerve-graft continuity.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Persons with severe sciatic nerve injury, brachial plexus injury, and/or major injury at the upper or lower extremity with nerve loss within previous year;
  • Peripheral nerve injury with large gap (5 - 10 cm) between healthy nerve endings;
  • Between the ages of 18 and 65 years at last birthday;

Exclusion Criteria:

  • Persons unable to safely undergo an MRI (may include persons with an implanted device or metallic fragments which may interfere with MRI safety);
  • Persons with pre-existing conditions that would preclude satisfactory sural nerve harvest (may include amputation or major injury to lower limb, or disease affecting the sural nerve);
  • Persons with severe peripheral nerve injury gap length > 10 cm in length;
  • Persons with history of radiation or local cancer in area of nerve injury, including primary tumors of the nerve;
  • Pregnant women or a positive pregnancy test in those women with reproductive potential prior to transplantation;
  • Presence of disease that might interfere with participant safety, compliance, or evaluation of the condition under study;
  • History of active substance abuse;
  • Persons allergic to gentamicin;
  • Persons who test positive for HIV or Hepatitis B or C virus;

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03999424


Contacts
Layout table for location contacts
Contact: Katie Gant, PhD 305-243-7108 mpinfo@med.miami.edu

Locations
Layout table for location information
United States, Florida
University of Miami Recruiting
Miami, Florida, United States, 33136
Contact: Katie Gant, PhD    305-243-7108    MPinfo@med.miami.edu   
Principal Investigator: Allan D Levi, MD, PhD         
Sponsors and Collaborators
W. Dalton Dietrich
The Miami Project to Cure Paralysis
Investigators
Layout table for investigator information
Principal Investigator: Allan Levi, MD, PhD University of Miami

Layout table for additonal information
Responsible Party: W. Dalton Dietrich, Professor, University of Miami
ClinicalTrials.gov Identifier: NCT03999424    
Other Study ID Numbers: 20190453
First Posted: June 26, 2019    Key Record Dates
Last Update Posted: September 26, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Nerve Injuries
Wounds and Injuries
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Trauma, Nervous System